Scienture Holdings (NASDAQ: SCNX) has secured several group purchasing organization (GPO) agreements that significantly expand institutional access to its overdose reversal therapy, REZENOPY™.
According to the company’s press release, the agreements provide potential access to more than 5,000 healthcare institutions across the United States, including hospitals, clinics, and nursing homes. In total, the partnerships could place the product within reach of roughly 60% of the U.S. institutional healthcare market.
Broad Institutional Reach Through GPO Partnerships
Group Purchasing Organizations allow healthcare providers to acquire medical products through centralized contracts and negotiated pricing. By entering these agreements, Scienture gains access to a large network of institutional buyers.
Importantly, the expanded distribution network extends beyond traditional hospital settings. It now includes first responders, emergency medical services teams, and rehabilitation centers.
Because of this wider reach, the company expects stronger adoption of the therapy across emergency care environments. Reflecting this view, Scienture president and co-CEO Narasimhan Mani described the agreements as a meaningful step in expanding the commercial footprint of REZENOPY™.
FDA-Approved Naloxone Spray Targets Opioid Overdose Emergencies
REZENOPY™ is a naloxone hydrochloride nasal spray designed to reverse opioid overdoses. The therapy received approval from the U.S. Food and Drug Administration on April 19, 2024.
The medication is intended for emergency use in both adults and children experiencing suspected opioid overdose. Each retail package contains two single-use intranasal spray devices.
Naloxone treatments are widely used by medical personnel and first responders because they counteract the life-threatening respiratory depression caused by opioids.
Demand for such treatments remains substantial. Healthcare analytics firm IQVIA estimates the U.S. naloxone market generates approximately $141 million in annual sales, with around 9.4 million prescription units recorded as of January 2026.
Commercialization Strategy and Licensing Background
Scienture’s ability to commercialize REZENOPY™ stems from a licensing agreement secured in March 2025. At that time, its subsidiary, Scienture, LLC, finalized a definitive agreement with Summit Biosciences Inc.
Under the deal, Scienture obtained exclusive rights to market the treatment in the United States. Summit Biosciences operates under Kindeva Drug Delivery L.P., a company specializing in advanced drug-delivery technologies.
Following the agreement, Scienture outlined a staged rollout plan. Distribution to wholesale channels is scheduled for the first quarter of 2026, with a broader commercial launch expected in the second quarter.
Patent Protection and Safety Profile
Alongside commercialization progress, the therapy also benefits from intellectual property protection. Earlier this year, the United States Patent and Trademark Office issued a patent covering the REZENOPY™ nasal spray.
The patent, granted to Summit Biosciences, remains valid until February 2041. This protection helps secure the product’s market position over the long term.
At the same time, the therapy carries standard safety considerations associated with naloxone products. The spray should not be used in patients with known hypersensitivity to naloxone hydrochloride.
Clinical warnings include the potential for recurrent respiratory depression after initial treatment, as well as the possibility of severe opioid withdrawal symptoms. Cardiovascular complications are also listed among potential risks.
In clinical studies, reported side effects included upper abdominal pain, nasopharyngitis, and altered taste perception.
Market Reaction and Company Financial Snapshot
Investors responded positively to the announcement. Shares of Scienture Holdings (NASDAQ: SCNX) jumped about 20% during afternoon trading, reaching $0.47.
Trading activity surged as well, with roughly 139.19 million shares changing hands—far above the stock’s typical daily volume of about 925,000 shares.
Despite the surge, the stock remains well below its 52-week high of $3.17. The current price sits roughly 84% below that peak.
Nevertheless, short-term momentum has improved. The shares have gained about 27% over the past week, though they remain down roughly 1% since the start of the year.
Scienture currently has a market capitalization of about $19.46 million. While the company remains unprofitable, with a reported loss of $1.81 per share, revenue growth has accelerated, increasing 208% over the past twelve months.
Additional Product Expansion Efforts
Beyond REZENOPY™, Scienture continues to broaden access to other products in its portfolio. Last month, the company secured new rebate agreements and institutional purchasing contracts for its liquid losartan formulation, ARBLI.
Those agreements extend access to more than 2,500 healthcare institutions and provide coverage for over 100 million individuals through major national health plans.
Stay on top of healthcare stocks with our Healthcare Stock updates.
